Majd Marzieh, Hashemian Farshad, Hosseini Seyed Mohammad, Vahdat Shariatpanahi Maryam, Sharifi Ali
Department of Clinical Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
Department of Psychiatry, Hamadan University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2015 Summer;14(3):891-9.
This study was designed to examine the antidepressant effect of celecoxib (200 mg/day) augmentation of sertraline in the treatment of female patients with first episode of major depression over 8 weeks of therapy. Thirty female outpatients diagnosed with first episode of major depression, were recruited for this study. Participants were randomly assigned into two equal groups receiving either sertraline plus celecoxib 100 mg twice daily or sertraline plus placebo twice daily. Patients were assessed by Hamilton Depression and Anxiety Rating Scale at baseline, week 4 and week 8 of treatment. Both treatment groups showed notable improvement in their symptoms from baseline; however, celecoxib group showed greater decrease in Hamilton Depression Scores compared to the placebo group after four weeks of treatment. Response rates were also found to be significantly higher in the celecoxib group compared to the placebo group over 4 weeks. Nevertheless, the mentioned differences between two groups were not significant at the end of week 8. Also, remission rate was remarkably higher in celecoxib group in comparison with placebo at the end point. The results suggested that celecoxib may hasten the onset of therapeutic action of sertraline and increase response and remission rate in depressive disorders.
本研究旨在探讨塞来昔布（200毫克/天）增强舍曲林治疗女性首发重度抑郁症患者8周的抗抑郁效果。30名被诊断为首发重度抑郁症的女性门诊患者被纳入本研究。参与者被随机分为两组，分别接受舍曲林加塞来昔布100毫克每日两次或舍曲林加安慰剂每日两次。在治疗的基线、第4周和第8周，通过汉密尔顿抑郁和焦虑评定量表对患者进行评估。两个治疗组的症状均较基线有显著改善；然而，治疗四周后，塞来昔布组的汉密尔顿抑郁评分较安慰剂组下降幅度更大。在4周内，塞来昔布组的缓解率也显著高于安慰剂组。然而，两组之间的上述差异在第8周结束时并不显著。此外，在终点时，塞来昔布组的缓解率明显高于安慰剂组。结果表明，塞来昔布可能会加速舍曲林的治疗作用起效，并提高抑郁症的缓解率和反应率。
